Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic optimization of omalizumab in allergic severe asthma by dose and frequency adjustment
2025-520782-48-00Phase 4Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in asthma, sponsored by Parc de Salut Mar. Primary endpoint: Maintenance of clinical stability after 50% omalizumab dose reduction. Planned start Jan 2025; status: authorised.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-520782-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520782-48-00.